GTHX — G1 Therapeutics Share News
0.000.00%
Last trade - 00:00- $377.22m
- $360.81m
- $82.51m
U.S. STOCKS ON THE MOVE-ARS Pharma, AMC, Eli Lilly
U.S. STOCKS ON THE MOVE-Arcutis Biotherapeutics, Akili, Tesla
G1 Therapeutics slips on J.P.Morgan cut to 'underweight'
Brief: Black Diamond Therapeutics Announces CEO Transition
G1 Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: G1 Therapeutics Q2 Basic EPS USD 0.17
G1 Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: G1 Therapeutics, Hercules Capital, Affiliates Enter Fifth Amendment To Loan, Agreement
U.S. STOCKS ON THE MOVE-Spotify, Akero Therapeutics, Cyxtera Technologies
U.S. STOCKS ON THE MOVE-Tesla, Moderna, Oil tanker firms
G1 Therapeutics rises on positive drug data from breast cancer trial
Brief: G1 Therapeutics Says Trilaciclib Increases Pool Of Memory T Cells In Tumor Microenvironment Responsible For Long Term Immune Surveillance, Efficacy
Brief: G1 Therapeutics Announces Appointment Of Monica Thomas As General Counsel
Brief: G1 Therapeutics Says Results From Phase 2 Trial Confirm Benefit Of Trilaciclib In Reducing Adverse Events Related To Antibody Drug Conjugate
G1 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: G1 Therapeutics Provides First Quarter 2023 Financial Results And Operational Highlights
Brief: G1 Therapeutics Inc - Company Does Not Hold Any Deposits At Svb Or Have Any Other Direct Investments At Svb
G1 Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: G1 Therapeutics Provides Fourth Quarter And Full Year 2022 Financial Results